Roth Conference kicks off March 23-24. Massive list of presenting companies but here are the biotech and healthcare names I'm watching:

GANX - Gain Therapeutics, $78M mcap. Fresh off AD/PD data in Parkinson's, now presenting at Roth same week.

ARCT - Arcturus Therapeutics, $209M mcap. mRNA platform, sub-$300M sweet spot.

CRVO - CervoMed, $50M mcap. Neuro, tiny.

CING - Cingulate, $52M mcap. ADHD program, just hit a 52-week high.

AVXL - Anavex, $435M mcap. Parkinson's/Alzheimer's.

CAPR - Capricor, $1.1B mcap. DMD gene therapy.

IBRX - ImmunityBio, $6B mcap. Larger name but active space.

LGND - Ligand, $3.7B mcap. Royalty model, good for deal flow intel.

PYPD - PolyPid, $79M mcap. Also on our Miami list.

NUVB - Nuvation Bio, $1.9B mcap. Also on our Miami list.

SPRY - ARS Pharma, $994M mcap. Also on our Miami list.

Three of these overlap with names we flagged at Miami Health Week. Want me to cover the Roth conference the way we covered Miami? Drop a comment and let me know.